Argenx SE (ARGX)
| Market Cap | 13.24B |
| Revenue (ttm) | 78.41M |
| Net Income (ttm) | -183.11M |
| Shares Out | 38.62M |
| EPS (ttm) | -1.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $279.22 |
| Previous Close | $282.17 |
| Change ($) | -2.95 |
| Change (%) | -1.05% |
| Day's Open | 279.58 |
| Day's Range | 278.02 - 282.86 |
| Day's Volume | 163,237 |
| 52-Week Range | 108.83 - 308.36 |
Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a dea...
Breda, the Netherlands – Jan. 8, 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and c...
January 4, 2021 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimm...
November 23, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoi...
BREDA, the Netherlands and GHENT, Belgium, Nov. 17, 2020 /PRNewswire/ -- argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from...
November 9, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoim...
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q3 2020 Results - Earnings Call Transcript
Shares of argenx (NASDAQ:ARGX) decreased 6.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 450.00% year over year to ($3.96), whi...
- Biologics License Application (BLA) for efgartigimod in generalized myasthenia gravis (gMG) on track to be submitted to U.S. Food and Drug Administration (FDA) by end of 2020 -
October 15, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoim...
September 2, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe au...
August 4, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoi...
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2020 Results - Earnings Call Transcript
July 30, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoim...
On Thursday, July 30, argenx (NASDAQ: ARGX) will release its latest earnings report.
argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Regulated information — Inside information
Regulated information — Inside information
argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.
Positive pivotal trial results are giving investors a reason to cheer.
Regulated information – Inside information
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2020 Results - Earnings Call Transcript
- Topline data readout from Phase 3 ADAPT trial of efgartigimod in generalized myasthenia gravis on track for mid-2020 and Biologics License Application filing by end of year - ...
Amid the COVID-19 pandemic, the investing pros say that it’s still possible to unmask names poised to take off on an upward trajectory.
Market Fairly Evaluates Argenx's Efgartigimod (ARGX-113) In Myasthenia Gravis
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2019 Results - Earnings Call Transcript
Top Ranked Momentum Stocks to Buy for February 27th
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The American Society of Hematology (ASH) hosted its 61st annual meeting, and one of the biggest biotech events, earlier this week in Orlando, Florida.
Regulated information – Inside information
Regulated information – Inside information
Biotechs trade on the prospects of new advancements to identify and treat diseases. That's something the world needs in good times and bad.
Shares have risen by 385% since my initial recommendation and by 120% since my last update.
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2019 Results - Earnings Call Transcript
Does ARGENX SE-ADR (ARGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
About ARGX
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer i... [Read more...]
| Industry Biotechnology | IPO Date May 18, 2017 |
| CEO Tim Van Hauwermeiren | Employees 186 |
| Stock Exchange NASDAQ | Ticker Symbol ARGX |
Financial Performance
In 2019, Argenx SE's revenue was 69.78 million, an increase of 224.84% compared to the previous year's 21.48 million. Losses were -162.97 million, 144.5% more than in 2018.
Analyst Forecasts
The average 12-month stock price forecast for Argenx SE is 304.30, which is an increase of 8.98% from the latest price.